Journal of Oncology Case Reports Online | Volume 2, Issue 1 | Case Report | Open Access DOI
Roberta Giorgione*
Roberta Giorgione1,2*, Lorenzo Di Stefano1,2, Carla Amato1,3, Marinella Micol Mela1, Fabrizio Di Maida2,4, Andrea Minervini2,4, Serena Pillozzi5, Giandomenico Roviello1,3, Lorenzo Antonuzzo1,2
1Oncology Unit, Careggi University Hospital, Florence 50134, Italy
2Department of Experimental and Clinical Medicine, University of Florence, Florence, 50134, Italy
3Health Sciences Department, University of Florence, Florence, 50134, Italy
4Unit of Urology and Andrology, Careggi University Hospital, Florence, 50134, Italy
5Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Florence, 50121, Italy
*Correspondence to: Roberta Giorgione
Fulltext PDFBladder cancer is a common urological malignancy, predominantly affecting older adults, and metastatic disease is associated with poor prognosis. We present the case of a 70-year-old woman with metastatic urothelial carcinoma presenting as a right subcutaneous axillary mass. First-line treatment with enfortumab vedotin, an anti–Nectin-4 antibody–drug conjugate, combined with the PD-1 inhibitor pembrolizumab resulted in a rapid and clinically significant regression of the lesion. This case illustrates a rare presentation of subcutaneous metastasis in urothelial carcinoma, suggestive of aggressive tumor biology. The dramatic response to enfortumab vedotin plus pembrolizumab underscores the potential efficacy of this combination in patient's ineligible for cisplatin-based chemotherapy. Early systemic therapy proved effective in controlling metastatic progression, even in the set setting of renal impairment and advanced age.
Metastatic urothelial carcinoma, Sub-cutaneous metastasis, Enfortumab vedotin, Pembrolizumab, Case report
Roberta Giorgione, Lorenzo Di Stefano, Carla Amato, Marinella Micol Mela, Fabrizio Di Maida, Andrea Minervini, et al. Rapid Regression of Rare Sub-Cutaneous Metastasis in Urothelial Carcinoma Patient Treated with Enfortumab Vedotin Plus Pembrolizumab: A Case Report. Jour Onco Case Rep Onl. 2026;2(1):1-7.